AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial. Here’s What It Means for a Stock Up 24% in 2026

Key Stats for AbbVie StockCurrent Price: $282. 68Target Price (Mid): ~$367Street Target: ~$283Potential Total Return: ~30%Annualized IRR: ~6% / yearWhat Happened?AbbVie (ABBV) presented primary Phase 2a results for ABBV-466, its investigational two-drug Crohn’s disease combination, at a gastroenterology meeting in Barcelona on October 19.